Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results and Highlights Recent Period Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- US futures fall on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Piper Jaffray Cuts PT on Alnylam (ALNY) by 45%; Keep 'Overweight'
February 12, 2016 8:26 AM ESTPiper Jaffray analyst, Edward Tenthoff, cut his Alnylam Pharmaceuticals (NASDAQ: ALNY) price target to $102 from $184 which still represents 79% upside from current levels. No change to Overweight rating.
Alnylam ended 2015 with cash of $1.28 billion and guided to end 2016 with >$850 million including a $100 million investment in an RNAi manufacturing facility. The company recently completed enrollment of >200 familial amyloidotic polyneuropathy (FAP) patients in the Phase III APOLLO trial setting up top-line data in 2H:17 and a potential launch in 2018. Alnylam is advancing and expanding its... More
Alnylam Pharma (ALNY) Misses Q4 EPS by 11c
February 11, 2016 4:15 PM ESTAlnylam Pharma (NASDAQ: ALNY) reported Q4 EPS of ($1.07), $0.11 worse than the analyst estimate of ($0.96). Revenue for the quarter came in at $7.6 million versus the consensus estimate of $9.1 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
... More